JP2007527430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007527430A5 JP2007527430A5 JP2007501976A JP2007501976A JP2007527430A5 JP 2007527430 A5 JP2007527430 A5 JP 2007527430A5 JP 2007501976 A JP2007501976 A JP 2007501976A JP 2007501976 A JP2007501976 A JP 2007501976A JP 2007527430 A5 JP2007527430 A5 JP 2007527430A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- group
- composition
- dry powder
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 54
- 238000009472 formulation Methods 0.000 claims 42
- 239000000546 pharmaceutical excipient Substances 0.000 claims 15
- 239000000725 suspension Substances 0.000 claims 15
- 239000000843 powder Substances 0.000 claims 12
- 239000012530 fluid Substances 0.000 claims 11
- 239000000126 substance Substances 0.000 claims 11
- 239000000758 substrate Substances 0.000 claims 11
- 239000002245 particle Substances 0.000 claims 10
- 239000000243 solution Substances 0.000 claims 10
- 239000003380 propellant Substances 0.000 claims 8
- 239000004094 surface-active agent Substances 0.000 claims 8
- 231100000252 nontoxic Toxicity 0.000 claims 7
- 230000003000 nontoxic effect Effects 0.000 claims 7
- 239000000443 aerosol Substances 0.000 claims 5
- 239000007900 aqueous suspension Substances 0.000 claims 5
- 229940071648 metered dose inhaler Drugs 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 239000006199 nebulizer Substances 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 230000000975 bioactive effect Effects 0.000 claims 2
- 229940124630 bronchodilator Drugs 0.000 claims 2
- 239000000168 bronchodilator agent Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229940112141 dry powder inhaler Drugs 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 239000012678 infectious agent Substances 0.000 claims 2
- 239000003595 mist Substances 0.000 claims 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 235000000346 sugar Nutrition 0.000 claims 2
- 150000008163 sugars Chemical class 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000007407 African swine fever Diseases 0.000 claims 1
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 claims 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 1
- 208000034784 Tularaemia Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 210000005058 airway cell Anatomy 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 208000020282 anthrax disease Diseases 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000006824 bubonic plague Diseases 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 229940066493 expectorants Drugs 0.000 claims 1
- 239000004744 fabric Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000004745 nonwoven fabric Substances 0.000 claims 1
- 210000001331 nose Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 230000000704 physical effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- -1 vapors Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 239000002759 woven fabric Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55060104P | 2004-03-05 | 2004-03-05 | |
| US56047004P | 2004-04-07 | 2004-04-07 | |
| US56418904P | 2004-04-21 | 2004-04-21 | |
| US57263104P | 2004-05-19 | 2004-05-19 | |
| US57942504P | 2004-06-14 | 2004-06-14 | |
| US10/990,996 US20050207983A1 (en) | 2004-03-05 | 2004-11-17 | Formulations decreasing particle exhalation |
| PCT/US2005/006903 WO2005084638A2 (en) | 2004-03-05 | 2005-03-03 | Formulations decreasing infectivity of pulmonary diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007527430A JP2007527430A (ja) | 2007-09-27 |
| JP2007527430A5 true JP2007527430A5 (https=) | 2007-12-20 |
Family
ID=34923561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007501976A Pending JP2007527430A (ja) | 2004-03-05 | 2005-03-03 | 肺疾患の感染性を低下させる処方物 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20050207983A1 (https=) |
| EP (1) | EP1732606A2 (https=) |
| JP (1) | JP2007527430A (https=) |
| AU (2) | AU2005219431B2 (https=) |
| CA (1) | CA2558426C (https=) |
| WO (1) | WO2005084638A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003243191B2 (en) * | 2002-05-02 | 2007-09-20 | President And Fellows Of Harvard College | Formulations limiting spread of pulmonary infections |
| US20050207983A1 (en) | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
| EP2402001A1 (en) | 2005-05-18 | 2012-01-04 | Pulmatrix, Inc. | Formulations for alteration of biophysical properties of mucosal lining |
| EP1834651A1 (en) * | 2006-03-15 | 2007-09-19 | Universiteit Gent | Compositions and methods for veterinary vaccination |
| WO2008055208A1 (en) * | 2006-11-01 | 2008-05-08 | New Jersey Institute Of Technology | Aerogel-based filtration of gas phase systems |
| US20080260863A1 (en) * | 2007-04-20 | 2008-10-23 | Pre Holding, Inc. | Compositions for mucociliary clearance and methods for administering same |
| EP2194867B1 (en) * | 2007-10-02 | 2021-06-02 | Anna-Carin Olin | Collection and measurement of exhaled particles |
| JP2012522011A (ja) * | 2009-03-26 | 2012-09-20 | パルマトリックス，インコーポレイテッド | 気道感染症を治療するための医薬製剤および方法 |
| CA2754691C (en) | 2009-03-26 | 2019-07-30 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| CA2754684A1 (en) * | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining |
| CA2754670A1 (en) * | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Anti-influenza formulations and methods |
| WO2012012498A2 (en) * | 2010-07-20 | 2012-01-26 | Pulmatrix, Inc. | Use of trp channel agonists to treat infections |
| AU2011296343B2 (en) | 2010-08-30 | 2015-12-10 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| EP2464346A1 (en) | 2010-08-30 | 2012-06-20 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| RU2017144619A (ru) | 2010-09-29 | 2019-02-20 | Пулмэтрикс, Инк. | Катионы одновалентных металлов сухих порошков для ингаляций |
| EP3470057B1 (en) | 2010-09-29 | 2021-11-03 | Pulmatrix Operating Company, Inc. | Cationic dry powders comprising magnesium salt |
| KR101211672B1 (ko) | 2010-12-10 | 2012-12-12 | 한국철도기술연구원 | 재채기 모사장치 및 모사방법 |
| CN107596518B (zh) | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | 可吸入干粉剂 |
| JP6473738B2 (ja) | 2013-04-01 | 2019-02-20 | パルマトリックス，インコーポレイテッド | チオトロピウム乾燥粉末 |
| WO2016067252A1 (en) | 2014-10-31 | 2016-05-06 | Glaxosmithkline Intellectual Property Development Limited | Powder formulation |
| MA41124A (fr) * | 2014-12-05 | 2017-10-10 | Sun Pharmaceutical Ind Ltd | Compositions en suspension à libération prolongée à rétention gastrique |
| EP3846825A4 (en) | 2018-09-05 | 2022-11-02 | Sensory Cloud, LLC | FORMULATIONS AND COMPOSITIONS FOR ORTHO- AND/OR RETRO-NASAL DELIVERY AND RELATED SYSTEMS, METHODS AND ARTICLES |
| US20220000767A1 (en) * | 2020-07-06 | 2022-01-06 | Sensory Cloud, Inc. | Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi |
| WO2022040247A1 (en) * | 2020-08-17 | 2022-02-24 | Massachusetts Institute Of Technology | Respiratory system simulator systems and methods |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3229179C2 (de) | 1982-08-05 | 1986-04-17 | A. Nattermann & Cie GmbH, 5000 Köln | Lungensurfactant |
| US4826844A (en) * | 1987-09-30 | 1989-05-02 | American Home Products Corporation | Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols |
| US4899914A (en) * | 1988-11-04 | 1990-02-13 | Ciba-Geigy Corporation | Method for producing a sterile preservative-free aerosol saline solution |
| US5230884A (en) * | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
| US5175152A (en) * | 1990-09-28 | 1992-12-29 | Singh Nikhilesh N | Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form |
| US5211944A (en) | 1990-10-12 | 1993-05-18 | Shaman Pharmaceuticals, Inc. | Proanthocyanidin polymers having antiviral activity and methods of obtaining same |
| US5466680A (en) | 1992-03-26 | 1995-11-14 | Cytologics, Inc. | Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface |
| JP3961029B2 (ja) | 1992-06-24 | 2007-08-15 | 博 木戸 | インフルエンザウィルス感染防止剤 |
| US5709202A (en) * | 1993-05-21 | 1998-01-20 | Aradigm Corporation | Intrapulmonary delivery of aerosolized formulations |
| AUPM411494A0 (en) * | 1994-02-25 | 1994-03-24 | Central Sydney Area Health Service | Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum |
| US5633003A (en) | 1994-03-31 | 1997-05-27 | Cantor; Jerome O. | Use of intratracheally administered hyaluronic acid to ameliorate emphysema |
| US5633033A (en) * | 1994-04-18 | 1997-05-27 | Matsushita Electric Industrial Co., Ltd. | Method for manufacturing chalcopyrite film |
| US5863563A (en) | 1994-10-20 | 1999-01-26 | Alphagene Inc. | Treatment of pulmonary conditions associated with insufficient secretion of surfactant |
| US5654007A (en) * | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US5628984A (en) * | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| GB9606677D0 (en) | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
| US6083922A (en) * | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| USRE37053E1 (en) * | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| DE19653969A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
| US5883084A (en) | 1998-06-08 | 1999-03-16 | Clarion Pharmaceuticals Inc. | Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine |
| SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| FR2780285B1 (fr) | 1998-06-29 | 2001-10-05 | Goemar Lab Sa | Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions |
| US6926911B1 (en) | 1998-12-22 | 2005-08-09 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
| US6083933A (en) * | 1999-04-19 | 2000-07-04 | Stellar International Inc. | Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution |
| AU2001278131A1 (en) * | 2000-08-01 | 2002-02-13 | Shofner Engineering Associates, Inc. | Generation, delivery, measurement and control of aerosol boli for diagnostics and treatments of the respiratory/pulmonary tract of a patient |
| CA2432319A1 (en) * | 2000-12-21 | 2002-07-18 | Nektar Therapeutics | Pulmonary delivery of polyene antifungal agents |
| PT2301524E (pt) * | 2000-12-27 | 2013-07-10 | Gilead Sciences Inc | Aztreonam inalável sem arginina para tratamento e prevenção de infecções bacterianas pulmonares |
| US20030138403A1 (en) * | 2001-06-29 | 2003-07-24 | Maxygen Aps | Interferon formulations |
| AU2003243191B2 (en) * | 2002-05-02 | 2007-09-20 | President And Fellows Of Harvard College | Formulations limiting spread of pulmonary infections |
| EP1503744A1 (en) * | 2002-05-13 | 2005-02-09 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
| US20050207983A1 (en) | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
| CA2602596A1 (en) | 2004-03-30 | 2005-10-13 | Malcolm King | Compositions and methods for improved mucus function |
| US8627821B2 (en) | 2005-01-10 | 2014-01-14 | Pulmatrix, Inc. | Method and device for decreasing contamination |
| WO2006102438A2 (en) | 2005-03-23 | 2006-09-28 | Ihc Intellectual Asset Management, Llc | Methods and compositions for irrigation of mucosal tissues |
| EP2402001A1 (en) | 2005-05-18 | 2012-01-04 | Pulmatrix, Inc. | Formulations for alteration of biophysical properties of mucosal lining |
-
2004
- 2004-11-17 US US10/990,996 patent/US20050207983A1/en not_active Abandoned
-
2005
- 2005-03-03 AU AU2005219431A patent/AU2005219431B2/en not_active Expired
- 2005-03-03 JP JP2007501976A patent/JP2007527430A/ja active Pending
- 2005-03-03 CA CA2558426A patent/CA2558426C/en not_active Expired - Lifetime
- 2005-03-03 WO PCT/US2005/006903 patent/WO2005084638A2/en not_active Ceased
- 2005-03-03 EP EP05757878A patent/EP1732606A2/en not_active Withdrawn
-
2007
- 2007-03-06 US US11/714,999 patent/US8187637B2/en active Active
-
2009
- 2009-10-14 AU AU2009225363A patent/AU2009225363B2/en not_active Expired
-
2012
- 2012-04-25 US US13/455,585 patent/US8591866B2/en not_active Expired - Fee Related
-
2013
- 2013-10-21 US US14/058,852 patent/US20150079173A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007527430A5 (https=) | ||
| CA2558426A1 (en) | Formulations decreasing particle exhalation | |
| Clark | Medical aerosol inhalers: past, present, and future | |
| EP1292347B1 (en) | Drug delivery apparatus | |
| ES2243094T3 (es) | Administracion de un agente activo aerosolizado modulado con resistentcia al flujo. | |
| Corr et al. | Design and characteristics of a portable breath actuated, particle size selective medical aerosol inhaler | |
| O'Callaghan et al. | The science of nebulised drug delivery | |
| US8820316B2 (en) | Drug delivery apparatus | |
| Lourenço et al. | Clinical aerosols: I. Characterization of aerosols and their diagnostic uses | |
| Dalby et al. | Medical devices for the delivery of therapeutic aerosols to the lungs | |
| Byron | Some future perspectives for unit dose inhalation aerosols | |
| JP2008049127A (ja) | 吸入装置 | |
| Taylor | Pulmonary drug delivery | |
| Bisgaard et al. | Spacer devices | |
| Fonceca et al. | Drug administration by inhalation in children | |
| Wolff et al. | Generation of aerosolized drugs | |
| de Boer et al. | Devices and formulations: General introduction and wet aerosol delivery systems | |
| Bhattacharyya et al. | Inhalation therapy–approaches and challenges | |
| Pongracic | Asthma delivery devices: age-appropriate use | |
| Fahad et al. | Mechanism and ways of pulmonary drug administration | |
| O′ Callaghan | Targeting drug delivery to the lungs by inhalation | |
| JP2023523035A (ja) | キニーネ及び先天性免疫応答を生じさせるためのその使用 | |
| CN114712336B (zh) | 一种用于肺部给药的水性气溶胶、制备方法和用途 | |
| Donn et al. | Aerosolization and Nebulization | |
| Benson et al. | Optimisation of Drug Delivery: 5. Pulmonary Drug Delivery |